v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating Expenses:        
Research and development $ 1,736,013 $ 2,753,963 $ 4,074,357 $ 5,661,790
General and administrative 2,110,453 1,969,828 4,617,837 4,012,532
Total Operating Expenses 3,846,466 4,723,791 8,692,194 9,674,322
Loss from Operations (3,846,466) (4,723,791) (8,692,194) (9,674,322)
Other Income (Expenses):        
(Loss) gain on foreign currency (52) 121
Derivative expense (3,103,533) (4,000,255)
Change in fair value of preferred stock liabilities 6,610,240 6,610,240
Change in fair value of earnout liability 19,500
Stock-based inducement expense (707,300) (863,550)
Interest income 1,025 13,776 4,174 14,626
Interest expense (690,044) (856,330)
Total Other Income (Expenses), net 2,817,636 (693,524) 1,777,450 (848,924)
Net Loss (1,028,830) (5,417,315) (6,914,744) (10,523,246)
Deemed dividend on Series A, B, C, D and E Preferred Stock (28,426,624) (24,700,374) (28,426,624) (24,964,518)
Deemed dividend related to Series C Common Warrants (84,083)
Net loss attributable to common shareholders $ (29,455,454) $ (30,117,689) $ (35,341,368) $ (35,571,847)
Net Loss per Common Share:        
Basic (in Dollars per share) $ (0.7) $ (61.71) $ (0.92) $ (107.6)
Diluted (in Dollars per share) $ (0.7) $ (61.71) $ (0.92) $ (107.6)
Weighted Average Common Shares Outstanding:        
Basic (in Shares) 42,175,020 488,076 38,567,412 330,603
Diluted (in Shares) 42,175,020 488,076 38,567,412 330,603